- Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) announced that the safety of SON-1010 dosing has been formally reviewed in both the current Phase 1 clinical trials, and the company is now enrolling the final dose cohort in the cancer trial.
- Of the 15 patients from the first five cohorts of SB101 evaluable for follow-up at this latest cutoff, 9 had stable disease at the first follow-up scan, 4 of which were already progressing at study entry.
- At four months of follow-up, 5 of 14 patients remained stable at the second scan, suggesting the clinical benefit of SON-1010 in 36% of patients.
- The first patient dosed with an aggressive endometrial sarcoma had target tumor shrinkage with complete resolution of ascites at one point and has been clinically stable for nearly a year.
- SON-1010 has been safe and tolerable at all doses tested to date, with adverse events generally mild/moderate in intensity and transient.
- Chardan Capital maintains a Buy rating on the stock with a price target of $17, down from $22.
- Price Action: SONN shares are down 8.97% at $0.30 on the last check Wednesday.
Slim Jim Enters The ‘Meataverse’: How You Can Get A Free NFT From The Dogecoin-Supporting Meat Snack Company
Fans of cryptocurrency likely know that meat stick and meat snacks company Slim Jim has been a supporter of the meme coin Dogecoin (CRYPTO: DOGE) for years.
